Several other research analysts have also recently commented on the company. TheStreet upgraded Quidel from a c+ rating to a b rating in a research note on Friday, November 1st. Zacks Investment Research upgraded Quidel from a sell rating to a hold rating in a research note on Wednesday, December 25th. ValuEngine cut Quidel from a hold rating to a sell rating in a research note on Tuesday, February 4th. Finally, Canaccord Genuity reiterated a buy rating and issued a $75.00 price target (up previously from $70.00) on shares of Quidel in a research note on Sunday, November 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $77.60.
Shares of QDEL opened at $80.40 on Tuesday. The stock’s 50-day moving average is $76.66 and its two-hundred day moving average is $66.38. The stock has a market cap of $3.23 billion, a PE ratio of 44.92 and a beta of 1.41. Quidel has a 12 month low of $52.49 and a 12 month high of $81.99. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.97.
Quidel (NASDAQ:QDEL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $1.00 EPS for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.18. The company had revenue of $152.20 million for the quarter, compared to analysts’ expectations of $148.00 million. Quidel had a return on equity of 22.48% and a net margin of 14.51%. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.80 earnings per share. On average, research analysts anticipate that Quidel will post 2.55 earnings per share for the current year.
In related news, SVP Ratan S. Borkar sold 4,700 shares of the business’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $70.00, for a total value of $329,000.00. Following the transaction, the senior vice president now owns 14,004 shares in the company, valued at $980,280. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Edward Keith Russell sold 15,974 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $68.73, for a total value of $1,097,893.02. Following the completion of the transaction, the senior vice president now owns 25,280 shares in the company, valued at approximately $1,737,494.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,625 shares of company stock worth $3,054,807. Insiders own 14.10% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. California Public Employees Retirement System increased its holdings in Quidel by 64.1% in the third quarter. California Public Employees Retirement System now owns 83,819 shares of the company’s stock valued at $5,142,000 after buying an additional 32,743 shares during the last quarter. Millennium Management LLC bought a new stake in Quidel in the third quarter valued at about $12,206,000. Barclays PLC increased its holdings in Quidel by 8.8% in the third quarter. Barclays PLC now owns 26,654 shares of the company’s stock valued at $1,636,000 after buying an additional 2,146 shares during the last quarter. California State Teachers Retirement System increased its holdings in Quidel by 1.2% in the third quarter. California State Teachers Retirement System now owns 55,173 shares of the company’s stock valued at $3,385,000 after buying an additional 659 shares during the last quarter. Finally, Carillon Tower Advisers Inc. increased its holdings in Quidel by 15.1% in the third quarter. Carillon Tower Advisers Inc. now owns 457,803 shares of the company’s stock valued at $28,086,000 after buying an additional 60,000 shares during the last quarter. 89.68% of the stock is owned by hedge funds and other institutional investors.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Recommended Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.